BANDUNG, Indonesia, Oct. 25, 2025 /PRNewswire/ -- Through PT Bio Farma (Persero), Indonesia has played a strategic and sustained role in the Developing Countries Vaccine Manufacturers' Network (DCVMN), working to ensure equitable access to safe, high-quality, and affordable vaccines. Since DCVMN's founding in 2000, Bio Farma has been a key driver in advancing vaccine self-reliance and public health capacity in developing countries.
Collaboration between Bio Farma and DCVMN has been established since the inception of the network. At the first DCVMN Annual General Meeting in Noordwijk in 2000, Bio Farma was one of ten founding members dedicated to advancing vaccine collaboration. In April 2001, Bio Farma in Bandung hosted the 2nd AGM, where the network formalized the DCVMN's structure and governance. Chaired by then-President Director Thamrin Poeloengan, this meeting established Indonesia as a hub for vaccine collaboration and knowledge-sharing among developing countries.
Shadiq Akasya, current President Director of Bio Farma, stated that the company's participation in DCVMN reflects Indonesia's commitment to contributing to global health beyond national interests.
"Bio Farma's involvement in DCVMN since its establishment is not merely about representation, but about making a tangible contribution toward global vaccine self-reliance. Through collaboration and innovation, we are committed to delivering equitable and sustainable health solutions for all," said Shadiq.
"We believe that the true strength of the developing countries' vaccine industry lies in collaboration. Through our active role in DCVMN, we aim to ensure that every nation has access to safe, high-quality, and affordable vaccines, a real manifestation of Indonesia's contribution to global health security," he added.
In 2004, Bio Farma, together with other DCVMN members, played a vital role in expanding access to the pentavalent (DPT-HepB-Hib) vaccine through a technology-transfer collaboration with the Netherlands Vaccine Institute. This achievement demonstrated that Bio Farma's contributions within the DCVMN network are not symbolic but deeply technical and practical.
Global trust in Bio Farma has continued to grow. In 2012, Indonesia once again hosted the 13th DCVMN AGM in Bali. Mahendra Suhardono, one of Bio Farma's directors at the time, was elected President of the Executive Committee for the 2013 - 2014 term.
Indonesia's leadership was further recognized when Bio Farma was entrusted to serve as Chair of the Board of DCVMN for the 2023-2025 period, acting as a bridge between network members and global strategic priorities, while showcasing Indonesia's capacity to lead the vaccine industry in developing countries.
Bio Farma's commitment to innovation goes far beyond collaboration. In 2020, its nOPV2 vaccine became the first to receive an Emergency Use Listing from the World Health Organization, enabling faster deployment of vaccines during global health emergencies. This achievement reflected not only Bio Farma's scientific and technical excellence but also effective coordination and communication among multiple international stakeholders, including funders, scientists, academic researchers, policymakers, global vaccine advocates, and vaccine manufacturers. Such collaboration enabled the rapid development, approval, and rollout of nOPV2 during a critical moment for global public health.
This milestone demonstrated that a developing-country manufacturer can achieve world-class innovation, meeting the highest international standards of safety, quality, and efficacy recognized by the WHO. Beyond being a scientific breakthrough, nOPV2 represents technological self-reliance and global confidence in Indonesia's capability to contribute meaningfully to international health security. Bio Farma's success serves as an inspiration to all DCVMN members to continue strengthening their research, development, and production capacity in pursuit of achieving vaccine self-sufficiency and global health resilience across developing countries.
With a production capacity of more than 3.5 billion doses per year, Bio Farma supplies vaccines to over 150 countries and holds WHO Prequalification certification for 12 types of vaccines. As the Center of Excellence for the Organization of Islamic Cooperation (OIC) in vaccine development, production, and distribution, Bio Farma continues to strengthen Indonesia's strategic role in the global health landscape.
The upcoming 26th DCVMN Annual General Meeting, to be held in Bali on 29–31 October 2025, marks an important moment for Indonesia to reaffirm its leadership in global health diplomacy. Through this forum, Bio Farma is committed to advancing innovation, collaboration, and vaccine self-reliance worldwide, toward a more resilient and equitable global health ecosystem.
About DCVMN
The Developing Countries Vaccine Manufacturers Network (DCVMN) is a global alliance of 46 vaccine manufacturers from 17 developing countries, established in 2000 to strengthen public health through equitable access to high-quality vaccines.
DCVMN promotes collaboration among its members through advocacy, capacity building, professional training, and joint research initiatives, aimed at enhancing global immunization programs.
Working closely with international organizations such as WHO, UNICEF, GAVI, CEPI, PATH, CHAI, and the Gates Foundation, DCVMN strives to ensure that every nation has the capability to produce and supply affordable, life-saving vaccines. For further information, please visit dcvmn.org.
About Bio Farma
PT Bio Farma (Persero) is Indonesia's state-owned life science company and the largest vaccine manufacturer in Southeast Asia.
Founded in 1890 and headquartered in Bandung, Bio Farma produces and supplies vaccines to more than 150 countries, while playing an active role in biotechnology research, innovation, and global health security.
As a member of DCVMN, Bio Farma continues to contribute to international collaboration to ensure equitable vaccine access and improved global public health. For further information, please visit www.biofarma.co.id.
Contact Us
PT Bio Farma (Persero)
Corporate Communication
Jl. Pasteur No.28 Bandung,
Jawa Barat Indonesia 40161
Website: www.biofarma.co.id
Email: corcom@biofarma.co.id
DCVMN
Route de Crassier, 7
CH-1262 Nyon
Switzerland
Website: dcvmn.org
Email: info@dcvmn.net
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Indonesia's Legacy in the Global Vaccine Landscape, Bio Farma and DCVMN Strengthen Health Resilience Through Global Partnership
|
VICTORIA, Seychelles, Jan. 28, 2026 /PRNewswire/ -- MEXC, the fastest-growing global cryptocurrency exchange, redefining a user-first approach to digital assets through true Zero-Fee trading, today released its 2025 Zero-Fee Strategy Annual Report. The ongoing commitment not only saved users a total of 1.1 billion USDT in fees but also bolsters both mainstream growth and emerging asset visibility, driving balanced development across the entire crypto landscape.
The platform's removal of fees across 3,026 spot trading pairs and 203 futures pairs resulted in significant savings for its users. Data shows 3.44 million users saved an average of $320 each, with the top single-user saving reaching $9 million. The move represented a significant shift in standard exchange fee models.
"We proved that Zero-Fee trading isn't a promotional tactic—it's a liquidity engine," the report states. The strategy delivered measurable competitive advantages, with MEXC capturing 72% market share in PUMPUSDT and 59% in LINKUSDT.
The "dual-market" approach demonstrated strategic precision: futures volume was anchored by mainstream assets (BTC& ETH made up 70% of the top 10), while emerging narratives surged. SUIUSDT ranked fourth, and USDC pairs exploded (BNBUSDC up 110x, SUIUSDC up 83x).
Zero-Fee proved particularly transformative for emerging assets. MNTUSDT gained 53% points in market share, while PUMP and LINK increased 42% and 34% respectively. The platform successfully bootstrapped new tokens while unlocking renewed trading potential in established assets across Layer 1s, DeFi, and oracle sectors.
In spot markets, MEXC established a commanding presence in the year's defining narrative: tokenized real-world assets (RWA). The exchange captured dominant market shares in leading tokenized equities—73% of McDonald's trading, 70% of Amazon, and 61% of Meta—while also securing 61% of Robinhood and 55% of Coinbase volume. This performance reinforced the platform's strategic "Widest Selection" positioning within the RWA landscape.
Since December 22, 2025, MEXC expanded Zero-Fee coverage to all spot trading pairs, removing the final barriers to entry for retail and institutional traders alike.
The report illustrates how MEXC's "MEXCmize, Zero-Fee, Infinite Opportunities" flywheel has transitioned from concept to a demonstrable market advantage. This was achieved by stripping away transaction costs to facilitate high-frequency strategies and providing consistent liquidity across the asset spectrum, thereby establishing a resilient competitive position.
"We're not just building the lowest-cost exchange," the report concludes. "We're building the premier crypto gateway defined by lowest costs and widest selection—empowering global users to capture market opportunities and maximize asset value."
Access the full report here.
About MEXC
Founded in 2018, MEXC is committed to being "Your Easiest Way to Crypto." Serving over 40 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.
MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC
VICTORIA, Seychelles, Jan. 28, 2026 /PRNewswire/ -- MEXC, the fastest-growing global cryptocurrency exchange, redefining a user-first approach to digital assets through true Zero-Fee trading, today released its 2025 Zero-Fee Strategy Annual Report. The ongoing commitment not only saved users a total of 1.1 billion USDT in fees but also bolsters both mainstream growth and emerging asset visibility, driving balanced development across the entire crypto landscape.
The platform's removal of fees across 3,026 spot trading pairs and 203 futures pairs resulted in significant savings for its users. Data shows 3.44 million users saved an average of $320 each, with the top single-user saving reaching $9 million. The move represented a significant shift in standard exchange fee models.
"We proved that Zero-Fee trading isn't a promotional tactic—it's a liquidity engine," the report states. The strategy delivered measurable competitive advantages, with MEXC capturing 72% market share in PUMPUSDT and 59% in LINKUSDT.
The "dual-market" approach demonstrated strategic precision: futures volume was anchored by mainstream assets (BTC& ETH made up 70% of the top 10), while emerging narratives surged. SUIUSDT ranked fourth, and USDC pairs exploded (BNBUSDC up 110x, SUIUSDC up 83x).
Zero-Fee proved particularly transformative for emerging assets. MNTUSDT gained 53% points in market share, while PUMP and LINK increased 42% and 34% respectively. The platform successfully bootstrapped new tokens while unlocking renewed trading potential in established assets across Layer 1s, DeFi, and oracle sectors.
In spot markets, MEXC established a commanding presence in the year's defining narrative: tokenized real-world assets (RWA). The exchange captured dominant market shares in leading tokenized equities—73% of McDonald's trading, 70% of Amazon, and 61% of Meta—while also securing 61% of Robinhood and 55% of Coinbase volume. This performance reinforced the platform's strategic "Widest Selection" positioning within the RWA landscape.
Since December 22, 2025, MEXC expanded Zero-Fee coverage to all spot trading pairs, removing the final barriers to entry for retail and institutional traders alike.
The report illustrates how MEXC's "MEXCmize, Zero-Fee, Infinite Opportunities" flywheel has transitioned from concept to a demonstrable market advantage. This was achieved by stripping away transaction costs to facilitate high-frequency strategies and providing consistent liquidity across the asset spectrum, thereby establishing a resilient competitive position.
"We're not just building the lowest-cost exchange," the report concludes. "We're building the premier crypto gateway defined by lowest costs and widest selection—empowering global users to capture market opportunities and maximize asset value."
Access the full report here.
About MEXC
Founded in 2018, MEXC is committed to being "Your Easiest Way to Crypto." Serving over 40 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.
MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
MEXC 2025 Report: Zero-Fee Strategy Delivers $1.1B in User Savings, Capturing Leading Market Share
